UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): |
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
|
||||
|
||||
(Address of Principal Executive Offices) |
|
(Zip Code) |
Registrant’s Telephone Number, Including Area Code: |
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 5.07. Submission of Matters to a Vote of Security Holders.
On June 8, 2023, Sight Sciences, Inc. (the “Company”) held its annual meeting of stockholders. A total of 41,709,886 shares of the Company’s common stock were present in person or represented by proxy at the meeting, representing approximately 86.1% of the Company’s common stock outstanding as of April 11, 2023, the record date. Set forth below are the voting results for the proposals considered and voted upon at the meeting, each of which are described in more detail in the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 26, 2023.
Item 1 – Election of two Class II directors to serve until the Company’s annual meeting of stockholders to be held in 2026 and until each such director’s respective successor has been duly elected and qualified or until each such director’s earlier death, resignation or removal.
|
|
Votes FOR |
|
|
Votes WITHHELD |
|
|
Broker Non-Votes |
|
|||
Staffan Encranz |
|
|
25,200,595 |
|
|
|
10,308,666 |
|
|
|
6,200,625 |
|
Catherine Mazzacco |
|
|
35,458,052 |
|
|
|
51,209 |
|
|
|
6,200,625 |
|
Item 2 – Ratification of the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023.
Votes FOR |
|
|
Votes AGAINST |
|
|
Votes ABSTAINED |
|
|
Broker Non-Votes |
|||
|
41,688,515 |
|
|
|
4,435 |
|
|
|
16,936 |
|
|
0 |
Based on the foregoing votes, Staffan Encrantz and Catherine Mazzacco were elected as Class II directors, and the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 was duly ratified.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
Sight Sciences, Inc. |
|
|
|
|
Date: |
June 12, 2023 |
By: |
/s/ Paul Badawi |
|
|
|
President and Chief Executive Officer |